arrow
V

Valeria Merz

university of verona
H指数:19
被引数:1,463

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages

作者更正:CCL3 预测在产生 LIF 的巨噬细胞富集的基底样胰腺癌中,TGFβ 抑制可产生卓越反应

2026-05-220
OA
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: updated analysis of survival and circulating and genetic biomarkers from the phase II nITRO trial

可切除胰腺导管腺癌患者的围手术期NALIRIFOX方案:来自II期nITRO试验的生存率及循环和遗传生物标志物的更新分析

2026-05-050
OAAI
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

可切除胰腺导管腺癌患者的围手术期NALIRIFOX: 开放标签,多中心,II期nITRO试验

2024-01-016
OA
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab

靶向FGFR通路不是曲妥珠单抗耐药的非选择性转移性食管胃癌患者的有效治疗策略

2023-03-111
OAAI
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

密码子特异性KRAS突变预测转移性结直肠癌中三氟尿苷/替匹拉西的生存益处

2023-03-0244
OAAI
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
2021-12-214
PRE
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

Tgf β 受体I激酶抑制剂galunisertib和anti-PD-L1抗体durvalumab在转移性胰腺癌中的安全性和活性

2021-03-09128
OAAI
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020-10-1512
OAAI
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial
2020-09-0410
OAAI
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

血浆IL8是TAK1激活的生物标志物,可预测吉西他滨难治性胰腺癌患者对纳米脂质体伊立替康的耐药性

2020-09-0122
OAAI
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
2020-07-0729
OAAI